Investigational drug · Phase 2
CHF6333
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Bronchiectasis.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "CHF6333"
First trial start
2023
Nov 29, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CHF6333", any sponsor or status.
Conditions studied
As listed on its trial records.
- Bronchiectasis
Approved drugs for the same conditions: Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "CHF6333" as an intervention, largest first.
- A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With BronchiectasisPivotal-lookingCompleted
Chiesi Farmaceutici S.p.A.Industry
NCT06166056 · 108 participants · Start Nov 29, 2023 · Primary completion Aug 27, 2026
Drug: CHF6333; CHF6333 Placebo · For: Bronchiectasis
Sites: Cambridge, United Kingdom; Dundee, United Kingdom; Edinburgh, United Kingdom · 8 sites in all
Chiesi Farmaceutici S.p.A.Industry
NCT03056326 · 72 participants · Start Nov 2016 · Primary completion Jul 2017
Drug: CHF6333 (Part 1 - SAD); Placebo (Part 1 - SAD) and 2 more · For: Non-Cystic Fibrosis Bronchiectasis; Cystic Fibrosis
Sites: Antwerp, Belgium
Chiesi Farmaceutici S.p.A.Industry
NCT04010799 · 68 participants · Start May 27, 2019 · Primary completion Mar 8, 2021
Drug: CHF 6333; Placebo · For: Cystic Fibrosis; Non-Cystic Fibrosis Bronchiectasis
Sites: Frankfurt am Main, Germany
Newest research
PubMed records naming it or its code names, newest first.
- Design, Synthesis, and Biological Evaluation of the Novel Neutrophil Elastase Inhibitor CHF-6333 for the Inhaled Treatment of Bronchiectasis.
Armani E, Rizzi A, Miglietta D, et al. · J Med Chem 2025
Also in development for Bronchiectasis
- ItepekimabREGN3500, SAR440340Phase 39 trials
Sanofi · Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps, Bronchiectasis
- VerducatibBI 1291583Phase 34 trials
Boehringer Ingelheim · Bronchiectasis, Chronic Obstructive Pulmonary Disease
- HSK31858Phase 33 trials
Haisco Pharmaceutical Group Co., Ltd. · Non-cystic Fibrosis Bronchiectasis, Asthma Bronchiale, Bronchiectasis
- CHF10196florensocatibPhase 31 trial
Chiesi Farmaceutici S.p.A. · Bronchiectasis
- GSK3862995BPhase 22 trials
GSK · Bronchiectasis, Pulmonary Disease, Chronic Obstructive
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.